'Newish' Artios Pharma snags former Lilly exec as CMO

April 1, 2019

Artios Pharma, a three-year-old DNA Damage Response biotech, developing a pipeline of cancer treatments, announced the appointment of Ian Smith, M.D., as Chief Medical Office.

Dr. Smith will assume responsibility for leading Artios's overall preclinical and clinical development strategy, regulatory, and medical activities. Smith was previously a senior medical director for Eli Lilly, working in oncology R&D.

Artios also announced the formation of a new Clinical Advisory Board with the appointment of world leading clinical oncologists.

The Cambridge, UK-based Artios, backed by Pfizer and Novartis, has a promising pipeline of DDR therapies, which offer opportunities to treat difficult cancers, providing new treatment options for patients.

Read the press release.